Letter to the editor regarding "At Birth, Tales of Joy and Heartbreak"
By Marcy Darnovsky,
New York Times
| 10. 14. 2009
To the Editor:
“The Gift of Life, and Its Price” reports that the fertility industry’s professional organization encourages its members to transfer fewer embryos, so as to produce fewer multiple pregnancies and premature babies. The organization, the American Society for Reproductive Medicine, is to be commended for these efforts.
But its guidelines are routinely flouted. The society could put teeth behind its rules by publicly suspending the memberships of fertility practices in noncompliance. And it has resisted calls for public regulation and oversight.
Recent experiences with the financial sector have dramatized the dangers of inadequate public policy. The fertility industry, too, demonstrates the limits of self-regulation. Public regulation must be carefully written and not used to advance other agendas like opposition to reproductive rights. It’s past time for the federal government to set rules for the fertility industry and establish ways to enforce them.
Marcy Darnovsky
Berkeley, Calif., Oct. 11, 2009
The writer is associate executive director of the Center for Genetics and Society.
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...